Cameron Santoro

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Elizabeth Jones, MD, FAAD, dermatologist at Thomas Jefferson University Hospitals, addresses the common issue of insurance companies preferring newer, […]

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease. | Image Credit: Nirusmee – stock.adobe.com The FDA approved guselkumab (Tremfya; Johnson &

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Steven Daniel Daveluy, MD, FAAD, associate professor, program director, and clinical educator at Wayne State University, discussed the potential

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. At the recent American Academy of Dermatology annual conference, Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, spoke on

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. At the recent American Academy of Dermatology (AAD) annual conference, leading experts in the field of dermatology convened to

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Brittany Craiglow, MD, FAAD, dermatologist at the Dermatology Physicians of Connecticut in Fairfield, discussed combination therapies for pediatric alopecia

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Lawrence F. Eichenfield, MD, FAAD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital and professor of dermatology

Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology (AAD) meeting. | Image

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Steven Daniel Daveluy, MD, FAAD, associate professor, program director, and clinical educator at Wayne State University, emphasizes the importance